Cypre is proud to present our poster with our partners at CRL titled “Automated 42 PDX 3D in vitro tumor models of the TME screen immuno-oncology and targeted compounds and biologics for antitumor effects and MOA” on Tuesday, April 9th at 9am-noon in Section 28 (Poster 23, Abstract 4703). The Poster will be available after the conference.

This joint technical data sheet with Charles River describes the Cypre 3D Tumor Model Platform for targeted and immunotherapy screening.

April 13, 2023: Cypre and Charles River publish a peer-reviewed manuscript detailing the Cypre 3D tumor platform, titled "A Novel Hydrogel-Based 3D In Vitro Tumor Panel of 30 PDX Models Incorporates Tumor, Stromal and Immune Cell Compartments of the TME for the Screening of Oncology and Immuno-Therapies"

Cypre presents a poster in collaboration with Charles River at the American Association for Cancer Research (AACR) conference titled “#1722 - KRAS, BRAF, BRCA1 and EGFR Mutation-Specific Panels Using Hydrogel-Based 3D In Vitro Tumor Models"

Cypre presents posters at the Society for Immunotherapy Conference (SITC) titled “#299 3D in vitro Tumor microenvironment models for screening CAR-T cell therapy efficacy.” , “#1447 A 30 PDX Panel of 3D in vitro tumor models identifies responders”

Cypre presented a joint poster with Charles River at AACR titled “#1880 - High throughput screening of 30 PDX cell lines in a 3D ECM hydrogel platform, incorporating tumor, stroma and immune components to demonstrate simultaneous investigation of multiple anti-tumor modalities”, highlighting the 3D Tumor Model Platform in screening 30 PDX models simulatenously with both small molecules and antibodies.

Cypre co-presented an invited Endpoints webinar with Charles River titled “Change the Game: An Examination of Cutting-Edge Novel Oncology Screening Tools.” The webinar is now available on-demand through the link below.

Cypre presents a joint publication with Charles River titled “How to build a tumor: An industry perspective”

We published a peer-reviewed research paper with our collaborators at Cedars Sinai Medical Center and Stanford, called “A Simple Three-dimensional Hydrogel Platform Enables Ex Vivo Cell Culture of Patient and PDX Tumors for Assaying Their Response to Clinically Relevant Therapies”, highlighting the utility of our technology in screening patient-derived tumors against small molecules.

Cypre presented a joint poster with Charles River at AACR titled “3184 - 3D in vitro tumor model platform for screening patient-derived NSCLC, CRC, and RCC tumors with targeted therapy and immunotherapy”, highlighting the 3D Tumor Model Platform in screening PDX models with both small molecules and antibodies.

Cypre co-presented a webinar with Charles River titled “Predict Anticancer Efficacy with a New In Vitro 3D Modeling Platform”. The webinar is now available on-demand through the link below.

We presented a minisymposium talk alongside our collaborators at Genentech called “An in vitro 3D immune exclusion tumor model engineered in a layer-by-layer fashion”, highlighting our platform’s application in creating the immune excluded phenotype with mouse cells and assaying T cell infiltration through our ECM hydrogel, VersaGel®, and subsequent T cell-mediated killing.